ArriVent BioPharma, Inc. (AVBP)
NASDAQ: AVBP · Real-Time Price · USD
24.64
+1.21 (5.16%)
Mar 9, 2026, 2:00 PM EDT - Market open
ArriVent BioPharma Employees
ArriVent BioPharma had 52 employees as of December 31, 2024. The number of employees increased by 12 or 30.00% compared to the previous year.
Employees
52
Change (1Y)
12
Growth (1Y)
30.00%
Revenue / Employee
n/a
Profits / Employee
-$3,198,231
Market Cap
1.09B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 52 | 12 | 30.00% |
| Dec 31, 2023 | 40 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| AbCellera Biologics | 596 |
| Pharming Group | 404 |
| Xeris Biopharma Holdings | 394 |
| UroGen Pharma | 287 |
| Geron | 229 |
| Inhibrx Biosciences | 161 |
| Inventiva | 84 |
| GH Research | 50 |
AVBP News
- 3 days ago - ArriVent BioPharma Reports Full Year 2025 Financial Results - GlobeNewsWire
- 2 months ago - ArriVent BioPharma: Its Leading Asset Furmonertinib Supports A Cautious Buy - Seeking Alpha
- 2 months ago - ArriVent BioPharma: A De-Risked Binary With Near-Term Catalysts - Seeking Alpha
- 2 months ago - ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer - GlobeNewsWire
- 4 months ago - ArriVent BioPharma Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 5 months ago - ArriVent Appoints Brent S. Rice as Chief Commercial Officer - GlobeNewsWire
- 6 months ago - Arrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung Cancer - GlobeNewsWire
- 7 months ago - ArriVent BioPharma Reports Second Quarter 2025 Financial Results - GlobeNewsWire